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CCDC26 on chromosome 8q24 is considered to encode a long intergenic noncoding RNA because the short open 
reading frame within the mRNA transcribed from this gene is not conserved in any other species. Genome-wide 
analysis has revealed association of CCDC26 with certain tumors, for instance low-level glioma. Moreover, 
moderate amplifications of the whole or part of the CCDC26 genetic locus have been observed in pediatric acute 
myeloid leukemia patients. The CCDC26 gene is amplified in the HL-60 acute myeloid leukemia cell line, in 
which double minute chromosomes—abnormal tiny chromosomes—harbor the CCDC26 gene. We examined the 
function of CCDC26 by gene knock-down (KD) using short hairpin RNAs in K562 human myeloid leukemia 
cells. In four stable KD clones, CCDC26 expression was suppressed to 1% of its normal level by transcriptional 
gene suppression, not post-transcriptional suppression. The growth rates of these KD clones were reduced 
compared with those of control cells in media containing high serum concentrations. In contrast, in media 
containing much lower serum concentrations, the KD clones exhibited significantly higher growth rates than 
controls, and increased survival after serum withdrawal. Enhanced expression of a receptor tyrosine kinase, 
KIT, was detected in the KD clones, and treatment with ISCK03, a KIT inhibitor, eliminated their increased 
survival in the absence of serum. Therefore, CCDC26 seems to control myeloid leukemia cell growth through 
regulation of KIT expression. These observations suggest that CCDC26 is a tumor-suppressive long noncoding 
RNA because it suppresses the KIT oncogene that supports survival of cancer cells in the stem cell state. 
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Introduction 
Noncoding RNAs (ncRNAs) have intrinsic functions 
without being translated into polypeptides. Classically, 
ncRNAs include 18S and 28S rRNAs that are transcribed by 
RNA polymerase I; and tRNA, 5S and other rRNAs that are 
transcribed by RNA polymerase III. ncRNAs also include 
two subsets: microRNAs (miRNAs) and long noncoding 
RNAs (lncRNAs) that are usually transcribed by RNA 
polymerase II. miRNAs are approximately 20 bp long and 
silence specific target genes, while lncRNAs extend from 
200 bp to several kb in length and have multiple roles in 
cellular functions and gene regulation. While the regulatory 
mechanisms of miRNAs acting on their targets through 
Argonaute protein are well documented, that of most 
lncRNAs remains to be fully elucidated [1]. 
In the last few years, there has been an exponential 
increase in the number of reports of lncRNA involvement in 
diseases such as cancer [2]. The role of lncRNAs, especially 
their regulatory role in gene expression, has received much 
attention because they could provide new diagnostic and 
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Figure1. (A) Summary of the genetic locus 8q24.21. The 8q24.21 region spans 126.1 Mb to 130.8 Mb 
(right to left; numbering is based on human genome assembly 37.1). Three of the regions amplified in HL-60 
are indicated by filled rectangles. Distal and peripheral breakpoint clusters (DBC and PBC, respectively) in 
dmin-positive AML patients are shown. (B) An enlarged part of 8q24.21 including the CCDC26 genetic locus, 
from 130.35 Mb to 130.80 Mb (right to left). Marks beneath the scale indicate the locations of six SNPs that 
are linked to glioma (rs4295627, rs16904140, rs55705857, rs6470745, rs891835, and rs10464870; open 
circles, left to right), and a retrovirus insertion site (filled circle). The locations of the amplified region in HL-60 
cells and the commonly amplified region (MAR) in childhood AML are shown by colored rectangles. The 
locations of NDME (Notch dependent MYC enhancer) and BDME (BRD dependent MYC enhancer) are 
indicated. Below them, which covers a 350-kb region, are shown the major variants of CCDC26 mRNA (long 
and short). The long transcript consists of four (1-2-3-4) exons, and the short transcript comprises three 
(1a-3-4) or four (1a-2a-3-4) exons. All variants share exons 3 and 4, in which the hypothetical ORF is 
encoded. Actively transcribed regions hAK015428, THS1, and THS2, which are not major exons of CCDC26 
mRNA, and the location of mir-3686, are indicated. The transcription scores are shown from RNA-seq 
experiments with whole cell and nuclear RNA from K562 myeloid leukemia cells, as are the patterns of 
histone H3K4 methylation and histone H3K27 acetylation. The bars at the bottom indicate regions with 
conserved synteny among mammals, as obtained from the UCSC Genome Browser[73].  
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therapeutic targets. Many lncRNAs have been shown to 
function in an oncogenic or anti-oncogenic manner. For 
example, ANRIL (breast cancer, and others) [3-5], CCAT1 
(colorectal cancer, gastric carcinoma, hepatocellular 
carcinoma) [6], H19 (bladder cancer) [7], HOTAIR (breast 
cancer, and others) [8, 9], MALAT-1 (lung cancer, and others) 
[10, 11], PCA3 (prostate cancer)[12, 13], and XIST (bladder cancer 
and others) [14, 15] have been shown to be correlated with 
tumor progression, while GAS5 (gastric carcinoma and 
others)[16, 17], LOC285194 (osteosarcoma) [18], MEG3 
(pituitary tumor and others) [19-21], and NDM29 
(neuroblastoma) [22] are considered putative tumor 
suppressors. Another several tens of lncRNAs suspected to 
be associated with tumors can be found in public databases 
[23]. The expression of several lncRNAs correlates well with 
cancer cell malignancy and could be used as a biomarker 
useful for diagnosis and prognosis. In particular, PCA3 has 
been established as one of the most reliable biomarkers of 
prostate cancer [24]. Meanwhile, there is also an increasing 
understanding of the molecular mechanisms of lncRNA 
regulation of cancer cell growth and metastasis. ANRIL, H19, 
HOTAIR, NDM29, and XIST interact with polycomb 
repressive complex 2 (PRC2) or its components to repress 
their target genes transcriptionally and epigenetically to 
progress malignancy [3, 7, 9, 15, 22]. CCAT-1 antagonizes its 
target miRNAs as a “sponge” to progress hepatocellular 
carcinoma [6]. MALAT-1 adjusts splicing mechanisms to 
regulate gene expression post-transcriptionally [25]. GAS5 
lncRNA functions as a tumor-suppressor through the 
mechanisms including suppression of certain steroid 
hormone receptors and sequestration of the miRNA, miR-21, 
in multiple cancer cells [17]. LOC285194 inhibits tumor cell 
growth through regulation of its target miRNA [18]. MEG3 
affects protein levels of the tumor suppressor p53 in lung 
cancer cells [21]. PCA3 is encoded on the antisense strand 
within the intron of the tumor suppressor gene PRUNE2. A 
unique lncRNA transcribed from PCA3 was shown to form 
double-stranded RNA with the premature RNA of PRUNE2 
to suppress it through ADAR (adenosine deaminase acting 
on RNA)-dependent adenosine-inosine RNA editing [13]. 
Although the mechanisms vary widely, most lncRNAs affect 
cancer cells through regulation of protein-encoding genes. 
Recently, clinical research has revealed that CCDC26, 
which encodes a protein with unknown function, is related to 
tumors including acute myeloid leukemia (AML) and 
glioma. In this review, we discuss the role of CCDC26 in 
myeloid leukemia with respect to its contribution to cell 
growth. 
CCDC26 is a putative intergenic long noncoding RNA 
Human transcriptome analysis revealed the existence of 
CCDC26, an mRNA-type lncRNA expressed in 
hematopoietic cells [26]. Figure 1 depicts an overview of the 
CCDC26 genetic locus. CCDC26 is located in a 350-kb 
region between LOC728724, another lncRNA, and GSDM, a 
hypothetical protein-coding proto-oncogene (Figure 1a). 
Therefore, CCDC26 is classified a long intergenic noncoding 
RNA (lincRNA), the function of which is unknown. There 
are two major splicing variants of the CCDC26 mRNA with 
common terminal exons (exons 3 and 4) (Figure 1b).  
A 109-amino-acid open reading frame (ORF) could be 
encoded within exon 4. The actual protein (Coiled Coil 
Domain Containing), however, has not been observed. 
Furthermore, homologous proteins are not found in any other 
species [26]. Therefore, this ORF could have arisen simply by 
accidental absence of the terminal codon. Regardless of 
whether the protein is functional, this ORF can work to 
prevent rapid degradation of CCDC26 RNA by 
nonsense-mediated RNA decay[27], which is a mechanism 
associated with quality control of mRNA—degrading 
mRNAs without a certain extent of ORF that are not useful 
for protein synthesis. The ORF on CCDC26 mRNA will 
prolong its half-life and may maintain the function (if any) of 
the CCDC26 RNA. The absence of a functional protein 
encoded by CCDC26 implies that it functions as an lncRNA 
not a protein-encoding mRNA.  
Several lines of evidence support a relationship between 
CCDC26 and tumors, including AML and glioma. Within 
this locus, particular regions are frequently rearranged in 
AML and AML-derived cells [28-30]. Single nucleotide 
polymorphisms (SNPs) associated with glioma[31, 32] and a 
retrovirus insertion site, where a viral insertion makes AML 
cells resistant to retinoic acid [33] indicated in Figure 1b will 
be discussed in detail later. 
High levels of histone methylation and acetylation were 
observed in several regions within the CCDC26 intron 
(Figure 1b), meaning that these locations may be actively 
transcribed. Furthermore most of these regions are highly 
conserved among mammals, again implying functionality. 
Moreover, transcripts other than the mature CCDC26 mRNA 
have been reported in the intron. Among them, miR-3686, an 
miRNA encoded in the intron of CCDC26 and registered in 
miRBase (http://www.mirbase.org/)[34] could play a role still 
unknown.  
Highly conserved regions in the introns of CCDC26 
suggest the existence of some further biological functions. 
By comparison of the syntenic region in mouse and other 
mammals, we found a homologous region in the CCDC26 
locus including CCDC26 exon 4 itself. A mouse lncRNA, 
AK015428, is considered to be related to mouse 
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spermatogenesis. The human homolog of AK015428, 
hAK015428, is another homologous region in the CCDC26 
locus: located upstream of the CCDC26 promoter and 
actively transcribed in human myeloid cells. hAK015428 
might be a promoter-related noncoding RNA of CCDC26 
[35]. Of note, the locations of CCDC26 exon 4 and 
hAK015428 are coincident with cis-elements, more than 1 
Mb from the MYC oncogene locus, NDME (Notch dependent 
Myc enhancer element), and BDME (Brd4-dependent Myc 
enhancer) (Figure 1b), which regulate MYC expression in 
human  and mouse T cell acute lymphoblastic leukemia cell 
lines [36]. However the significance of this coincidence is 
unclear. It is possible that CCDC26 exon4 and hAK015428 
function as enhancer-associated RNAs [37]. In summary, there 
might be biologically functional regions in the introns and 
upstream of CCDC26 in addition to in its exons. 
CCDC26 in glioma 
Associations between particular SNPs with primary brain 
tumor (PBT) were discovered by genome-wide association 
studies (GWAS) [31]. Glioma is a tumor of glial cells 
accounting for a major part of PBT, and contains cases with 
different stages of malignancy, namely benign glioma (grade 
I), diffuse astrocytoma (grade II), anaplastic astrocytoma 
(grade III), and glioblastoma (grade IV) [38]. Genetic 
mutations characteristic of glioma have been reported to 
occur in genes for six DNA repair enzymes, (PRKDC, 
XRCC, PARP1, MGMT, ERCC1 and ERCC2), epidermal 
growth factor (EGF) and interleukin 13 (IL13) [38]. 
Furthermore, a GWAS revealed association of another five 
genes with glioma, including TERT (telomere reverse 
transcriptase), RTEL1 (regulator telomeric elongation 
helicase 1), CDKN2A/2B (a tumor suppressor), PHLDB1 
(pleckstrin homology-like domain family B member 1), and 
CCDC26 [31]. All these genes except CCDC26 are 
protein-coding genes that are interconnected in biological 
networks. On the other hand, CCDC26 is a 
non-protein-coding gene, the function of which remains 
utterly unknown [38]. The CCDC26 gene locus was strongly 
associated with glioma through five SNPs including 
rs4295627, rs16904140, rs6470745, rs891835, and 
rs10464870 [39-42]. Another, higher-resolution GWAS 
revealed the strongest association in the CCDC26 locus: 
rs55705857 with PBT [32, 43]. A specific nucleotide in a 
CCDC26 SNP is a risk factor in low-grade (I–II) glioma, but 
not necessarily in high grade (III–IV) glioma cases [44]. A 
different SNP in the intergenic region, 400 kb downstream of 
CCDC26, rs987525, was linked to cleft palate that is also a 
risk factor for PBT [45]. Therefore, cleft palate might have 
relationship with PBT through CCDC26. 
There might be a synergistic effect with other cancer 
genetic risk factors. CCDC26 genotype is associated with 
mutation of the metabolic enzymes isocitrate dehydrogenase 
1 and 2 (IDH1/2) in low-grade glioma [46]. These IDH1/2 
mutations affect enzymatic activity to reduce α-ketoglutarate 
levels and elevate 2-hydroxyglutarate levels. This results in 
suppression of certain gene-regulatory proteins, including 
HIF1 through altered histone modification [47]. Considering 
the synergy of CCDC26 with IDH1/2, CCDC26 may be 
linked to a certain subpopulation of gliomas [46, 48]. A recent 
GWAS on pediatric PBT demonstrated associations with 
genes including RTEL1, TERT, and CCDC26; these are in 
common with associations identified in adult PBT. 
Additional to these, another noncoding RNA was 
identified—ANRIL (CDKN2B-AS), which down-regulates 
CDKN2B via an antisense transcript—and the tumor 
suppressor gene CDKN2B is related to adult PBT [49]. 
Interestingly, although ANRIL and RTEL1 are significantly 
related to astrocytoma, TERT and CCDC26 are stronger risk 
factors in the non-astrocytoma subtype of pediatric PBT. 
These observations suggest that pediatric and adult PBT 
share common genetic risk factors involving CCDC26, and 
similar etiological pathways that are related to the specific 
subcategory of PBT. 
CCDC26 in acute myeloid leukemia 
Acute myeloid leukemia (AML) is characterized by 
mutations in a set of genes that can be divided into two 
classes [50-52]. One class includes genes related to the 
proliferation or survival of cells and includes FLT3, ABL, 
RAS, and KIT, and the other consists of genes related to cell 
differentiation: HOXA9, AML1, MLL, NPM1, and RARα. 
Mutations in genes of both classes are required to give rise to 
AML. 
CCDC26 was reported to be associated with 
differentiation and apoptosis of PLB985 cells (a myelocytic 
leukemia cell line) induced by treatment with retinoic acid 
(CCDC26 is also known as RAM, for ‘retinoic acid 
modifying’). In isolated cells that had acquired resistance to 
retinoic acid after transduction with a retrovirus vector, 
insertion of the viral DNA in the intron of CCDC26 was 
observed Although knock-down (KD) of CCDC26 with 
RNA interference had little influence on the cells in ordinary 
conditions, retinoid acid-induced differentiation and 
apoptosis was significantly promoted [33]. Retinoic acid 
induces differentiation and apoptosis of not only some types 
of leukemia cells but also of neuroblastoma and glioblastoma 
cells, through modification of transcriptional regulation. 
Therefore CCDC26 might affect the differentiation state of 
these cells, too. 
A genome-wide study revealed that CCDC26 is most 
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frequently changed in childhood AML patients. Radtke and 
colleagues investigated copy number alterations (CNAs) in 
pediatric AML using comprehensive SNP array analysis, and 
found the most common CNA, occurring in 14% (15 of 111) 
of pediatric AML patients, to be on chromosomal loci 8q24 
with a low-burden copy number increase (2.83–3.77 copies) 
[53]. Four out of 15 cases indicated focal CNA and the other 
11 indicated CNA in a broader region including trisomy 8, 
which occurs frequently in AML [54]. They had a common 
altered region (MAR)—a 20-Mb region of 8q24—which 
interestingly contains part of the CCDC26 intron and exon 
(Figure 1b). 
We described that CCDC26 was expressed at 10–100 
molecules per cell in cell lines from AML (HL-60, ML-1, 
039/TSU, KG-1, GDM-1, SKNO-1), acute monocytic 
leukemia (THP-1), and chronic myeloid leukemia (CML) 
(K562, Meg-01, KU-812, MYLR). Very low expression 
(estimated at one molecule per cell) was observed in 
megakaryoblastic cells derived from leukemia accompanied 
with Down’s syndrome (CMK) and in monocytic leukemia 
cells derived from histiocytic lymphoma (U937). No 
expression was observed in T lymphocytic leukemia cells 
(Jurkat), Burkitt’s lymphoma cells (Raji), or 
non-hematopoietic cells, including U251MG (astrocytoma) 
and HeLa (cervical cancer) cells. Moderate expression was 
observed in bone marrow cells (our unpublished result) and 
normal monocytes (the Gene Expression Omnibus database 
[55] accession ID; GDS2251). These data indicated that 
expression of CCDC26 is strictly limited to myeloid cells of 
hematopoietic origin, suggesting specific roles for CCDC26 
in myeloid cells.  
Notably, in accord with the situation for low-grade 
glioma, mutations of IDH1/2 are important for diagnosis and 
prognostic prediction in AML patients [56]. While 
cytogenetically normal AML patients with an NPM1 
(nucleophosmin1) mutation and a normal FL3 gene is 
associated with favorable outcomes, AML patients with 
IDH1/2 mutation in addition to the same genetic background 
show adverse prognosis with poorer remission. Combined 
with the observation that CCDC26 is up-regulated in the 
NPM1-mutated subset of AML [57], CCDC26 and IDH1/2 are 
also implied to share synergistic responsibility for AML. 
The CCDC26-containing 8q24 locus is a hot spot for 
chromothripsis in AML 
Our own studies and those of others have shown that all or 
part of the CCDC26 gene is often amplified in AML cells 
harboring aberrant tiny extrachromosomal elements or 
double minute chromosomes (referred to as dmins). Dmins 
are cytogenetic abnormalities sometimes observed in AML 
cells although less commonly [28-30]. In HL-60 cells, two or 
four repeats of a 1.8-Mb amplification unit (amplicon) 
constitute their dmins. The amplicon is derived from several 
truncated regions of a 4.6-Mb region of chromosomal loci 
8q24, contains an intact MYC oncogene. In addition to MYC, 
several other genes, including CCDC26 and tribbles homolog 
1 (TRIB1), are also encoded on the amplicon (Figure 1a) and 
actively transcribed. Transcription of all these genes was 
significantly suppressed accompanied with differentiation of 
HL-60 induced by treatment with anticancer drug, indicating 
that they might be related to the cancerous nature of cells. 
The anticancer drug hydroxyurea blocks proliferation of 
HL-60 cells by promoting exclusion of dmins. Even after 
exclusion of dmins, MYC of the original chromosomal locus 
remained intact, but was no longer transcribed [58]. These 
observations suggest aberrant gene(s) on dmins other than 
MYC might be responsible for proliferation of HL-60 cells.  
As a result of chromosomal rearrangement, the CCDC26 
gene on dmin in HL-60 cells is changed to an incomplete 
form without exon 4 (which encodes the ORF) to produce 
abnormal transcripts [30]. Common breaking points in the 
CCDC26 locus have been found in dmin of AML patients 
and AML cell lines (Figure 1b), suggesting the common 
mechanism behind the generation of dmins in AML cells. 
Dmin in HL-60 consists of several segments spanning a 200 
to 700-kb genomic region, which have been joined by 
non-homologous recombination (our published [30] and 
unpublished observations). Such defective chromosomal 
rearrangements occurring in an extensive but limited 
chromosomal region are termed “chromothripsis”, a 
mechanism that explains the cytogenetic abnormalities often 
observed in cancerous cells [59]. 
CCDC26 is a tumor suppressor gene, but might not be an 
oncogene 
Fusion of BCR and ABL (BCR/ABL) is well known to be 
sufficient to cause CML [60]. However, an acute blastic crisis 
of CML is often accompanied by mutation of genes that are 
also mutated in AML, such as HOXA9 or AML [61, 62]. Thus, 
hematopoietic tyrosine kinases, including FLT3, ABL, RAS, 
and KIT, seem to play a similar role in AML and CML [63]. 
Considering the importance of imatinib, an ABL tyrosine 
kinase inhibitor used in the treatment of BCR/ABL-positive 
CML, inhibitors of other tyrosine kinases are likely to 
become increasingly important for the treatment of AML [60, 
64]. 
KIT is a receptor tyrosine kinase that is considered to play 
a role in AML because of its frequent up-regulation in 
patients. Expression of KIT in leukemia stem cells (LSCs) 
from pediatric AML patients who relapsed after 
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chemotherapy was increased compared with that in patients 
who did not relapse [65]. In work we have recently 
published[66], we obtained K562 cells in which CCDC26 
expression was constitutively knocked down with a short 
hairpin RNA to 1% of the level in the original K562 cells 
(called KD cells). Although KD cells grew at similar rate to 
the original cells in normal conditions, their growth slowed 
down in high-serum (15%) conditions. On the other hand, 
KD cells proliferated at a higher rate than the original cells in 
low-serum (0.1%) conditions. Moreover, in no-serum 
conditions, significantly fewer CCDC26-KD cells died than 
did original K562 cells. In these conditions, the original 
K562 cells stopped proliferating and died slowly, and cell 
death occurred in the G2/M cell cycle phase rather than the 
G1 phase. Therefore, under serum starvation, suppression of 
CCDC26 resulted in a prevention of cell death at a specific 
point in the cell cycle, and more surviving cells.  
DNA microarray analysis demonstrated that the gene 
expression profile in CCDC26-KD cells was shifted from 
that of the original cells, indicating that CCDC26 regulates 
the expression of a set of genes, although the mechanism 
remains unknown. Moreover, CCDC26 and some 
neighboring genes including GSDM and LOC728724 
undergo transcriptional down-regulation in KD cells. This 
regulation seems to involve epigenetic transcriptional 
repression because treatment with 2′-deoxy-5-azacytidine 
and trichostatin A to release epigenetic silencing partially 
reversed this repression. However an influence on MYC has 
yet to be observed. Among the genes that show altered 
expression in CCDC26-KD cells, the activation of 
endogenous KIT is highly interesting. Point mutations in KIT 
that enhance tyrosine kinase activity are frequently 
accompanied by the chromosomal translocation t(8;21) in 
adult AML, which results in poor prognosis[67]. We 
confirmed the presence of endogenous KIT protein, with a 
normal molecular weight and canonical localization, in KD 
cells. ISCK03, a KIT inhibitor, abolished this prolonged 
survival. This provides evidence for a new role for CCDC26 
in myeloid leukemia through the regulation of a set of genes 
including KIT. The concept that CCDC26-KIT regulation is 
key to survival of leukemia cells is important from the 
therapeutic viewpoint. KIT is an important gene in many 
different biological aspects [68]. KIT protein is a receptor for 
stem cell factor, which is expressed in the stromal cells of 
bone marrow and is necessary for self-renewal and 
maintaining hematopoietic stem cells in an undifferentiated 
state. In leukemia, malignant potential is considered to be 
tightly related to LSCs continuing self-renewal in the 
undifferentiated state. LSCs with CD34+ and CD38− surface 
markers are reportedly a cause of AML recurrence because 
they have the potential to survive in a special 
microenvironment, namely niche sites where they can escape 
the influence of drugs [69]. CCDC26-KD cells might share 
some properties with LSCs, including relatively slow growth 
and the ability to survive under certain conditions, such as a 
shortage of growth factors. Constitutive activation of KIT 
might contribute to the survival of these cells by an autocrine 
mechanism involving stem cell factor [70]. Although LSCs are 
usually negative for surface KIT protein in de novo AML [71], 
the existence of KIT-positive LSCs is related to an increased 
tendency of pediatric AML recurrence after chemotherapy. 
This can arise from constitutive activation of KIT protein [72]. 
Survival of KD cells was sensitive to the KIT inhibitor 
ISCK03 in a dose-dependent manner. After ISCK03 
treatment, the survival of KD cells was suppressed to the 
same level as that of non-KD cells. Therefore, KIT inhibitors 
are a potential strategy for the treatment of myeloid leukemia 
harboring an altered CCDC26 genetic locus. The 
down-regulation of KIT, a well-known oncogene, by 
CCDC26 suggests that it functions as a tumor suppressor 
gene. On the other hand, the amplified copy number of 
CCDC26 in some AML cases is conflicting. This paradox is 
explicable as follows. The low-burden increased copy 
number of CCDC26 is only partial and does not extend 
across the whole gene. Therefore this CNA might reflect the 
situation that CCDC26 is broken and corrupted into partially 
multiplicate forms at the internal chromothripsis hotspot. 
Moreover, the partial increased copy number and high 
expression of part of CCDC26 observed in HL-60 cells 
might be able to interfere with the function of the intact 
original gene. This explanation is consistent with the 
hypothesis that CCDC26 functions in a tumor-suppressive 
manner, and is not tumor promoting. 
Conclusion 
The current evidence suggests that the lncRNA CCDC26 
is not oncogenic, but an anti-oncogene that down-regulates 
the oncogene KIT. KIT inhibitors might be effective in the 
treatment of cancers with CCDC26 mutation, because the 
KIT receptor tyrosine kinase plays a role in the survival of 
cancer stem cells in their niche. 
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